215 related articles for article (PubMed ID: 16304393)
1. Chronic lymphocytic leukemia (CLL): first-line treatment.
Hallek M;
Hematology Am Soc Hematol Educ Program; 2005; ():285-91. PubMed ID: 16304393
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukaemia--moving towards cure?
Hillmen P
Lancet; 2010 Oct; 376(9747):1122-4. PubMed ID: 20888976
[No Abstract] [Full Text] [Related]
3. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia.
Visco C; Finotto S; Pomponi F; Sartori R; Laveder F; Trentin L; Paolini R; Di Bona E; Ruggeri M; Rodeghiero F
Am J Hematol; 2013 Apr; 88(4):289-93. PubMed ID: 23450436
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.
Hallek M
Am J Hematol; 2015 May; 90(5):446-60. PubMed ID: 25908509
[TBL] [Abstract][Full Text] [Related]
5. Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.
Byrd JC; Smith L; Hackbarth ML; Flinn IW; Young D; Proffitt JH; Heerema NA
Cancer Res; 2003 Jan; 63(1):36-8. PubMed ID: 12517774
[TBL] [Abstract][Full Text] [Related]
6. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K; Weiss L; Krause B; Melchardt T; Greil R
Eur J Haematol; 2013 Apr; 90(4):349-50. PubMed ID: 23278160
[No Abstract] [Full Text] [Related]
7. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
8. Advances in the diagnosis and treatment of chronic lymphocytic leukemia.
Abbott BL
Clin Adv Hematol Oncol; 2004 Jul; 2(7):448-54. PubMed ID: 16163221
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival.
Zenz T; Stilgenbauer S
Leuk Lymphoma; 2009 Oct; 50(10):1559-61. PubMed ID: 19701850
[No Abstract] [Full Text] [Related]
12. Novel immune-based treatment strategies for chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Keating MJ
J Clin Oncol; 2005 Sep; 23(26):6325-32. PubMed ID: 16155015
[TBL] [Abstract][Full Text] [Related]
13. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
Tam CS; Shanafelt TD; Wierda WG; Abruzzo LV; Van Dyke DL; O'Brien S; Ferrajoli A; Lerner SA; Lynn A; Kay NE; Keating MJ
Blood; 2009 Jul; 114(5):957-64. PubMed ID: 19414856
[TBL] [Abstract][Full Text] [Related]
14. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in chronic lymphocytic leukemia.
Jaglowski SM; Byrd JC
Semin Hematol; 2010 Apr; 47(2):156-69. PubMed ID: 20350663
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy of chronic lymphocytic leukemia.
Tam CS; Keating MJ
Best Pract Res Clin Haematol; 2007 Sep; 20(3):479-98. PubMed ID: 17707835
[TBL] [Abstract][Full Text] [Related]
17. The influence of different chromosomal aberrations on molecular cytogenetic parameters in chronic lymphocytic leukemia.
Amiel A; Leopold L; Gronich N; Yukla M; Fejgin MD; Lishner M
Cancer Genet Cytogenet; 2006 Jun; 167(2):145-9. PubMed ID: 16737914
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing and treating chronic lymphocytic leukemia in 2009.
Kaufman M; Rubin J; Rai K
Oncology (Williston Park); 2009 Nov; 23(12):1030-7. PubMed ID: 20017285
[TBL] [Abstract][Full Text] [Related]
20. Variability of ZAP 70 expression in a patient with CLL.
Chaar BT; Grosso L; Petruska PJ
Am J Hematol; 2006 Aug; 81(8):645. PubMed ID: 16823829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
